RAD51 and neoplasm: These two opposing roles of RAD52-dependent SSA make it a potential target of chemotherapy to treat RAD51-deficient tumour, as RAD52 inactivation may specifically inhibit the tumour growth and block additional rearrangements of chromosomes.